|Bid||144.34 x 1100|
|Ask||144.60 x 900|
|Day's range||141.83 - 144.97|
|52-week range||117.08 - 189.07|
|Beta (5Y monthly)||0.26|
|PE ratio (TTM)||3.39|
|Earnings date||27 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||02 Jun 2022|
|1y target est||208.90|
Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugsThe new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in manufacturing an important starting material for its oncology and COVID-19 vaccine pipeline The investment of approximately €40 million is part of a long-term development plan for BioNTech’s manufacturing site in Marburg German Chancellor Olaf Scholz is visiting the facility together with BioNTech co-founders
Today is shaping up negative for BioNTech SE ( NASDAQ:BNTX ) shareholders, with the analysts delivering a substantial...
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.